Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. - Wikidata - thesis-toulmin - TriplyDB

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

http://www.wikidata.org/entity/Q45858310

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Genetic engineering with T cell receptors Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity Reversal of tumor immune inhibition using a chimeric cytokine receptor.Engineered T cells for cancer treatment Immunotherapy in acute leukemia T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.Genetic modification of T cells for immunotherapy.Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.Adoptive cellular immunotherapy for childhood malignancies.Immunotherapy targeting EBV-expressing lymphoproliferative diseases Cancer-associated fibroblasts as targets for immunotherapy Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

P2860

Q21131200-1C3B236A-76C4-4FEE-96BA-A172D4DC6AE8 Q26995677-A4AD4B70-88E4-48F3-9838-856E8A307990 Q28075996-27F62B7B-0445-4D10-9FE7-E20B518E899F Q30580134-E17EC1E7-E266-4D1A-AA86-D37C94A16C1D Q33578792-10465FBC-F907-4E17-9101-1579666C60BF Q33731552-1E196A06-8DCD-4FFA-A1F0-A00F949C8BDD Q36427080-153F4BCB-5D67-4CB7-8D0D-3A1C2964717E Q36801053-8DAFBCFA-D504-47BE-BC54-8A8B12374CE7 Q36909362-540BED38-8FB7-4D58-B232-CE13EF894C92 Q36963494-770EBF4D-285B-44CA-92AD-A47086846DD6 Q37008216-E9660C27-5A3C-4ACE-8E95-08C7FDBFAC81 Q37268305-68FAC07E-711E-436E-9F7A-C95C160E6B51 Q38063582-6496C8DC-8FF6-4FAB-9F19-F3A27E4171E1 Q38570061-9C2BDBBE-AA92-43B7-A36F-CC258C1343E6 Q38719148-49A64CEF-C305-4F7D-847F-792C94FF99CD Q38848219-7E256D4E-DBEF-43DC-BFAE-C8EAD97891B5 Q39984618-3DFA0669-C5A8-4892-BC4F-19A5362660A4 Q42408344-7AA1FA38-424B-4CF4-B813-3B1E20DD4788

P2860

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

http://www.wikidata.org/entity/Q45858310

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@en

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@nl

type

label

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@en

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@nl

prefLabel

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@en

Assessing the safety of cytoto ...... g growth factor-beta receptor.

@nl

P1433

Q45858310-EEE9B255-73C0-46B3-BA17-19E894695FD1

P1476

Q45858310-D2744AC8-A114-48DF-83D7-5CAF2ED7752D

P2093

Q45858310-1C91185B-5CB4-4981-AB4C-D8E0503C6368

Q45858310-839C9703-3E61-40A9-8AA1-127D1B1A7F7E

Q45858310-9DFBD1F6-F47B-43B5-890D-902E08D22F8F

Q45858310-AB03FB76-A4F8-42CF-A3FB-E983AE01146E

Q45858310-ABF3BF74-9773-4624-8D9F-581853564CD2

Q45858310-B1C97EFD-988F-4B4E-B733-9783FEECA2D4

Q45858310-B34DE244-FF73-4FD5-8394-5A3437B21391

Q45858310-C8F3ACAB-E7B7-438D-90DF-68BC5FA06733

Q45858310-CB368476-F700-445F-8607-9333FD0DB381

Q45858310-F27CE6DE-BA92-41E7-B035-B4D7CEFE9EE7

P304

Q45858310-E771008F-E16B-47B8-A584-E3909F83C248

P31

Q45858310-C6C4288D-BDE6-48BE-8940-DBC863D80E6E

P356

Q45858310-C7A4A466-2FF7-442E-9730-C8AF26A7519D

P433

Q45858310-99A73515-24B4-4F7C-A849-904801C023CB

P478

Q45858310-8FA0FADE-D4D1-423C-A27B-F16D404B0747

P50

Q45858310-91C82B4D-54E2-4D69-8672-6EDFD561F62D

Q45858310-D80DFE01-05AF-463D-8C5B-852D7124221C

P577

Q45858310-8090B424-68BE-4162-BE95-BCF82FBF48B9

P698

Q45858310-6724E8FF-9B91-4DE6-9199-1003782379A2

P921

Q45858310-3CF9630C-05D9-4A23-B05B-B7DDDB1AFFA4

P356

01.CJI.0000192104.24583.CA

P1433

Journal of Immunotherapy

P1476

Assessing the safety of cytoto ...... ng growth factor-beta receptor

@en

P2093

Catherine M Bollard

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Elizabeth Buza

http://www.w3.org/2001/XMLSchema#string

Hans Hauser

http://www.w3.org/2001/XMLSchema#string

Heidi Weiss

http://www.w3.org/2001/XMLSchema#string

Helen E Heslop

http://www.w3.org/2001/XMLSchema#string

Kristine Lacuesta

http://www.w3.org/2001/XMLSchema#string

Laura Granville

http://www.w3.org/2001/XMLSchema#string

Malcolm K Brenner

http://www.w3.org/2001/XMLSchema#string

Milton Finegold

http://www.w3.org/2001/XMLSchema#string

P304

250-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CJI.0000192104.24583.CA

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16699368

http://www.w3.org/2001/XMLSchema#string

P921